Drug-induced liver injury: The role of drug metabolism and transport

Journal of Clinical Pharmacology

Volumn 53, Issue 5, 2013, Pages 463-474

  Corsini, Alberto ^a   Bortolini, Michele ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b Safety Risk Management   (Switzerland)

Author keywords

Drug metabolism; Drug induced liver injury; Hepatic transporter; Susceptibility

Indexed keywords

ANTINEOPLASTIC AGENT; BOSENTAN; CARBAMAZEPINE; CYCLOSPORIN; DICLOFENAC; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; ISONIAZID; METHOTREXATE; RIFAMPICIN; RITONAVIR; SULFONAMIDE; TICLOPIDINE; TROGLITAZONE;

ADAPTIVE IMMUNITY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG CONJUGATION; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; GENETIC SUSCEPTIBILITY; HUMAN; REVIEW; TOXIC HEPATITIS;

ANIMALS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS;

EID: 84880157804     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.23     Document Type: Review

References (168)

1. Lee WM. Acute liver failure in the United States. Semin Liver Dis. 2003;23(3):217-226. (Pubitemid 37052447)
2. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947-954. (Pubitemid 35440240)
3. Garcia-Cortes M, Stephens C, Lucena MI, Fernandez-Castaner A, Andrade RJ. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol. 2011;55(3):683-691.
4. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 2001;24(7):483-490. (Pubitemid 32595761)
5. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA. 2002;287(17):2273-2275. (Pubitemid 34441944)
6. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010;51(2):615-620.
7. Bernal W, Cross TJ, Auzinger G, et al. Outcome after wait-listing for emergency liver transplantation in acute liver failure: a single centre experience. J Hepatol. 2009;50(2):306-313.
8. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10(8):1018-1023. (Pubitemid 39232756)
9. Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics. 2009; 10(9):1467-1487.
10. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem. 2009;16(23):3041-3053.
11. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ. 1999; 319(7224):1541.
12. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis. 2007;11(3): 477-505. (Pubitemid 47302343)
13. Stirnimann G, Kessebohm K, Lauterburg B. Liver injury caused by drugs: an update. Swiss Med Wkly. 2010;140:w13080. http://www. smw.ch/content/smw-2010- 13080/. Accessed May 9, 2012.
14. Kenne K, Skanberg I, Glinghammar B, et al. Prediction of druginduced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol In Vitro. 2008;22(3):730-746.
15. Giacomini KM, Sugiyama Y. Membrane transporters and drug response. In: Brunton LL, Chabner B, Knollman B, eds. Goodman & Gilman's Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw Hill; 2011: 89.
16. Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;299(3):825-831. (Pubitemid 33104948)
17. Aoyama T, Yamano S, Waxman DJ, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem. 1989;264(18):10388-10395. (Pubitemid 19161599)
18. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39:1-17. (Pubitemid 29222549)
19. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1998;90(16):1225- 1229. (Pubitemid 28407089)
20. Shimada T, Gillam EM, Sandhu P, Guo Z, Tukey RH, Guengerich FP. Activation of procarcinogens by human cytochrome P450 enzymes expressed in Escherichia coli. Simplified bacterial systems for genotoxicity assays. Carcinogenesis. 1994;15(11): 2523-2529. (Pubitemid 24343686)
21. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996;59(5):491-502. (Pubitemid 26193889)
22. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687-710. (Pubitemid 350190847)
23. Gonzalez FJ, Coughtrie M, Tukey RH. Drug metabolism. In: Brunton LL, Chabner B, Knollman B, eds. Goodman & Gilman's Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw Hill; 2011: 123-144.
24. Andrade RJ, Robles M, Lucena MI. Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opin Drug Saf. 2009;8(6): 709-714.
25. Glatt H. Sulfation and sulfotransferases 4: bioactivation of mutagens via sulfation. FASEB J. 1997;11(5):314-321. (Pubitemid 27193935)
26. Strange RC, Spiteri MA, Ramachandran S, Fryer AA. Glutathione- S-transferase family of enzymes. Mutat Res. 2001;482(1-2): 21-26.
27. Zhou S, Chan E, Duan W, Huang M, Chen YZ. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev. 2005;37(1):41-213. (Pubitemid 40259715)
28. Glatt H, Engelke CE, Pabel U, et al. Sulfotransferases: genetics and role in toxicology. Toxicol Lett. 2000;112-113:341-348. (Pubitemid 30138142)
29. Glatt H. Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact. 2000;129(1-2):141-170. (Pubitemid 32061058)
30. Glatt H, Boeing H, Engelke CE, et al. Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat Res. 2001;482(1-2):27-40. (Pubitemid 32787079)
31. Hinson JA, Forkert PG. Phase II enzymes and bioactivation. Can J Physiol Pharmacol. 1995;73(10):1407-1413. (Pubitemid 26024399)
32. Ritter JK. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact. 2000;129(1-2):171-193. (Pubitemid 32061059)
33. Sallustio BC, Sabordo L, Evans AM, Nation RL. Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr Drug Metab. 2000;1(2):163-180.
34. Spahn-Langguth H, Dahms M, Hermening A. Acyl glucuronides: covalent binding and its potential relevance. Adv Exp Med Biol. 1996;387:313-328. (Pubitemid 26259260)
35. van Bladeren PJ. Glutathione conjugation as a bioactivation reaction. Chem Biol Interact. 2000;129(1-2):61-76. (Pubitemid 32061054)
36. Boelsterli UA. Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr Drug Metab. 2002;3(4): 439-450. (Pubitemid 34778006)
37. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit. 2003;25(1):1-16. (Pubitemid 36139819)
38. Antoine DJ, Williams DP, Park BK. Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. Expert Opin Drug Metab Toxicol. 2008;4(11):1415-1427.
39. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9(3):215-236.
40. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693-705.
41. Lee EJ, Lean CB, Limenta LM. Role of membrane transporters in the safety profile of drugs. Expert Opin Drug Metab Toxicol. 2009;5(11):1369-1383.
42. Abe T, Unno M, Onogawa T, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001;120(7): 1689-1699. (Pubitemid 32523487)
43. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004;447(5):653-665. (Pubitemid 38241451)
44. Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica. 2008;38(7-8):778-801.
45. Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol. 2000;278(1): G156-G164. (Pubitemid 30108080)
46. Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem. 2000;275(30):23161-23168. (Pubitemid 30646210)
47. Johnstone RW, Tainton KM, Ruefli AA, et al. P-glycoprotein does not protect cells against cytolysis induced by pore-forming proteins. J Biol Chem. 2001;276(20):16667-16673.
48. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75(1):13-33. (Pubitemid 38130115)
49. Aleksunes LM, Slitt AM, Cherrington NJ, Thibodeau MS, Klaassen CD, Manautou JE. Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. Toxicol Sci. 2005;83(1):44-52. (Pubitemid 40123329)
50. Geier A, Kim SK, Gerloff T, et al. Hepatobiliary organic anion transporters are differentially regulated in acute toxic liver injury induced by carbon tetrachloride. J Hepatol. 2002;37(2):198-205. (Pubitemid 34833081)
51. Ghanem CI, Gomez PC, Arana MC, et al. Effect of acetaminophen on expression and activity of rat liver multidrug resistanceassociated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004;68(4):791-798. (Pubitemid 38953461)
52. Song IS, Lee YM, Chung SJ, Shim CK. Multiple alterations of canalicular membrane transport activities in rats with CCl(4)- induced hepatic injury. Drug Metab Dispos. 2003;31(4):482-490.
53. Aleksunes LM, Campion SN, Goedken MJ, Manautou JE. Acquired resistance to acetaminophen hepatotoxicity is associated with induction of multidrug resistance-associated protein 4 (Mrp4) in proliferating hepatocytes. Toxicol Sci. 2008;104(2):261-273. (Pubitemid 352038249)
54. Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and druginduced cholestasis. Hepatology. 2006;44(4):778-787.
55. Ott P, Ranek L, Young MA. Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency. Eur J Clin Pharmacol. 1998;54(7):567-571. (Pubitemid 28487379)
56. Nozawa T, Sugiura S, Nakajima M, et al. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos. 2004;32(3):291-294. (Pubitemid 38263886)
57. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001;69(4):223-231. (Pubitemid 32382504)
58. Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol. 2001;59(3):627-635. (Pubitemid 32179943)
59. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000;118(2):422-430. (Pubitemid 30067515)
60. Akashi M, Tanaka A, Takikawa H. Effect of cyclosporin A on the biliary excretion of cholephilic compounds in rats. Hepatol Res. 2006;34(3):193-198.
61. Ah YM, Kim YM, Kim MJ, et al. Drug-induced hyperbilirubinemia and the clinical influencing factors. Drug Metab Rev. 2008; 40(4):511-537.
62. Kato R, Nishide M, Kozu C, et al. Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2? Eur J Clin Pharmacol. 2010;66(2):153-158.
63. FDA/Guidance for industry: drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. Draft guidance. Food and Drug Administration Web site. http://www.fda.gov/downloads/Drugs/ GuidanceCompliance RegulatoryInformation/Guidances/UCM292362.pdf. February 2012. Accessed May 9, 2012.
64. FDA/Drugs/Development resources page. Drug development and drug interactions: table of substrates, inhibitors and inducers. Food and Drug Administration Web site. http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/ DevelopmentResources/DrugInteractionsLabeling/ ucm093664.htm. Updated September 16, 2011. Accessed May 9, 2012.
65. DeLeve L, Kaplowitz N. Prevention and therapy of drug-induced hepatic injury. In: Wolfe MM, ed. Therapy of Digestive Disorders. Philadelphia: WB Saunders, Harcourt, Brace; 2000: 334-348.
66. Au JS, Navarro VJ, Rossi S. Review article: drug-induced liver injury - its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther. 2011;34(1):11-20.
67. Meyer UA, Gut J. Genomics and the prediction of xenobiotic toxicity. Toxicology 2002;181-182:463-466. (Pubitemid 36015738)
68. Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol. 1997;26(Suppl. 2):12-21.
69. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22(2):145-155. (Pubitemid 34496468)
70. Pachkoria K, Lucena MI, Ruiz-Cabello F, Crespo E, Cabello MR, Andrade RJ. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol. 2007;150(6):808-815. (Pubitemid 46440210)
71. Sevilla-Mantilla C, Ortega L, Agundez JA, Fernandez-Gutierrez B, Ladero JM, Diaz-Rubio M. Leflunomide-induced acute hepatitis. Dig Liver Dis. 2004;36(1):82-84. (Pubitemid 41122230)
72. Caccia S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet. 1998;34(4):281-302. (Pubitemid 28163404)
73. Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit. 2004;26(2):127-131. (Pubitemid 38501205)
74. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut. 1984;25(10):1057-1064. (Pubitemid 14002119)
75. Otani K, Kaneko S, Tasaki H, Fukushima Y. Hepatic injury caused by mianserin. BMJ. 1989;299(6697):519.
76. Seybold U, Landauer N, Hillebrand S, Goebel FD. Senna-induced hepatitis in a poor metabolizer. Ann InternMed. 2004;141(8):650-651.
77. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53(2):111-122. (Pubitemid 34264265)
78. Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology. 2003;37(4):924-930.
79. Sun F, Chen Y, Xiang Y, Zhan S. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis druginduced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2008;12(9):994-1002.
80. Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol. 2006;62(6):423-429. (Pubitemid 44069498)
81. Wang T, Yu HT, Wang W, Pan YY, He LX, Wang ZY. Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients. J Int Med Res. 2010;38(3):977-986.
82. An HR, Wu XQ, Wang ZY, Zhang JX, Liang Y. NAT2 and CYP2E1 polymorphisms associated with antituberculosis druginduced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol. 2012;39(6):535-543.
83. Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol. 2011;26(2):312-318.
84. Cho HJ, Koh WJ, Ryu YJ, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb). 2007;87(6):551-556.
85. Lee SW, Chung LS, Huang HH, Chuang TY, Liou YH, Wu LS. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis. 2010;14(5):622-626.
86. Tang SW, Lv XZ, Zhang Y, et al., CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis druginduced hepatotoxicity: a nested case-control study. J Clin Pharm Ther. 2012;37(5):588-593.
87. Teixeira RL, Morato RG, Cabello PH, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz. 2011;106(6):716-724.
88. Ariyoshi N, Iga Y, Hirata K, et al. Enhanced susceptibility of HLAmediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese. Drug Metab Pharmacokinet. 2010;25(3):298-306.
89. Miners JO, McKinnon RA, Mackenzie PI. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology. 2002;181-182:453-456. (Pubitemid 36015736)
90. Chang JC, Liu EH, Lee CN, et al. UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications. Int J Tuberc Lung Dis. 2012;16(3):376-378.
91. Lankisch TO, Moebius U, Wehmeier M, et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology. 2006;44(5):1324-1332. (Pubitemid 44748383)
92. Lankisch TO, Behrens G, Ehmer U, et al. Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy - an extended haplotype of genetic variants increases risk in indinavir treatment. J Hepatol. 2009;50(5):1010-1018.
93. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007;132(1):272-281. (Pubitemid 46108755)
94. Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med. 1976;84(2):181-192.
95. Dickinson DS, Bailey WC, Hirschowitz BI, Soong SJ, Eidus L, Hodgkin MM. Risk factors for isoniazid (NIH)-induced liver dysfunction. J Clin Gastroenterol. 1981;3(3):271-279. (Pubitemid 11053230)
96. Gronhagen-Riska C, Hellstrom PE, Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis. 1978;118(3):461-466. (Pubitemid 9027187)
97. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35(4): 883-889.
98. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a casecontrol study. Thorax. 1996;51(2):132-136. (Pubitemid 26060649)
99. Parthasarathy R, Sarma GR, Janardhanam B, et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with shortcourse regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle. 1986;67(2):99-108. (Pubitemid 16080227)
100. Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to anti-tuberculosis druginduced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2012;16(5):589-595.
101. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 1986;105(2):179-184. (Pubitemid 16039289)
102. Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol. 2007;47(1):128-134.
103. Leiro V, Fernandez-Villar A, Valverde D, et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int. 2008;28(6):835-839. (Pubitemid 351818646)
104. Roy B, Chowdhury A, Kundu S, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol. 2001;16(9) 1033-1037. (Pubitemid 32947147)
105. Chatterjee S, Lyle N, Mandal A, Kundu S. GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm Ther. 2010;35(4):465-470.
106. Kim SH, Kim SH, Yoon HJ, et al. GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans. Tuberculosis (Edinb). 2010;90(1):39-43.
107. Ueda K, Ishitsu T, Seo T, et al. Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics. 2007;8(5):435-442. (Pubitemid 46746351)
108. Chalasani N, Bjornsson E. Risk factors for idiosyncratic druginduced liver injury. Gastroenterology. 2010;138(7):2246-2259.
109. Lucena MI, Andrade RJ, Martinez C, et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology. 2008;48(2): 588-596.
110. Simon T, Becquemont L, Mary-Krause M, et al. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000;67(4):432-437. (Pubitemid 30246823)
111. Usui T, Hashizume T, Katsumata T, Yokoi T, Komuro S. In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. Drug Metab Dispos. 2011;39(7):1303-1310.
112. Watanabe I, Tomita A, Shimizu M, et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2003;73(5):435-455. (Pubitemid 36549828)
113. Lucena MI, Garcia-Martin E, Andrade RJ, et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology. 2010;52(1):303-312.
114. Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics. 2007;17(1):47-60. (Pubitemid 46183791)
115. Choi JH, Ahn BM, Yi J, et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics. 2007;17(6):403-415. (Pubitemid 46763385)
116. Andrade RJ, Crespo E, Ulzurrun E, et al. Polymorphic bile salt export pump transporter is a major determinant of hepatocellular drug-induced liver injury. Hepatology. 2008;48(Suppl. S1):468A. Abstract 353.
117. Meier Y, Zodan T, Lang C, et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J Gastroenterol. 2008;14(1):38-45. (Pubitemid 351314324)
118. Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 2006;372(6):432-443.
119. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statininduced myopathy - a genomewide study. N Engl J Med. 2008; 359(8):789-799.
120. Takane H, Kawamoto K, Sasaki T, et al. Life-threatening toxicities in a patient with UGT1A1-6/-28 and SLCO1B1-15/-15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol. 2009;63(6):1165-1169.
121. Trevino LR, Shimasaki N, Yang W, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009;27(35):5972-5978.
122. Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, Huang CS. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res. 2004;56(5):682-689.
123. van de Steeg E, Stranecky V, Hartmannova H, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest. 2012;122(2):519-528.
124. Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol. 1998;11(9):969-988. (Pubitemid 28447286)
125. Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem Res Toxicol. 1999;12(5):387-395. (Pubitemid 29352401)
126. Boelsterli UA, Zimmerman HJ, Kretz-Rommel A. Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Crit Rev Toxicol. 1995;25(3):207- 235.
127. Dansette PM, Bonierbale E, Minoletti C, Beaune PH, Pessayre D, Mansuy D. Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet. 1998;23(4):443-451. (Pubitemid 29184839)
128. Pichler WJ. Pharmacological interaction of drugs with antigenspecific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol. 2002;2(4):301-305. (Pubitemid 36869638)
129. Pichler WJ. Direct T-cell stimulations by drugs - bypassing the innate immune system. Toxicology 2005;209(2):95-100. (Pubitemid 40568634)
130. Burkhart C, von GS, Depta JP, et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazolespecific and sulfamethoxazole- metabolite-specific human CD4+ T-cells. Br J Pharmacol. 2001;132(3):623-630. (Pubitemid 32165177)
131. Schnyder B, Burkhart C, Schnyder-Frutig K, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol. 2000; 164(12):6647-6654. (Pubitemid 30408852)
132. Ju C, McCoy JP, Chung CJ, Graf ML, Pohl LR. Tolerogenic role of Kupffer cells in allergic reactions. Chem Res Toxicol. 2003; 16(12):1514-1519. (Pubitemid 38049370)
133. Ju C, Pohl LR. Tolerogenic role ofKupffer cells in immune-mediated adverse drug reactions. Toxicology. 2005;209(2):109-112. (Pubitemid 40568636)
134. Knolle PA, Schmitt E, Jin S, et al. Induction of cytokine production in naive CD4(+) T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells. Gastroenterology. 1999;116(6):1428-1440. (Pubitemid 29258892)
135. Limmer A, Ohl J, Kurts C, et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+T cells results in antigenspecific T-cell tolerance. Nat Med. 2000;6(12):1348-1354. (Pubitemid 32001018)
136. Pillarisetty VG, Shah AB, Miller G, Bleier JI, DeMatteo RP. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J Immunol. 2004;172(2):1009-1017. (Pubitemid 38113760)
137. You Q, Cheng L, Kedl RM, Ju C. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology. 2008; 48(3):978-990.
138. Schvarcz R, Rudbeck G, Soderdahl G, Stahle L. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation. 2000;69(10):2194-2195. (Pubitemid 30395060)
139. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42(9):819-850. (Pubitemid 36995083)
140. Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol. 2005;97(4):249-256. (Pubitemid 41433700)
141. Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Curr Med Res Opin. 2011;27(8):1551-1562.
142. Poirier A, Funk C, Lave T, Noe J. New strategies to address drugdrug interactions involving OATPs. Curr Opin Drug Discov Dev. 2007;10(1):74-83. (Pubitemid 46438260)
143. Corsini A, Bellosta S. Drug-drug interaction with statins. Expert Rev Clin Pharmacol. 2008;1(1):105-113.
144. Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81(2):194-204. (Pubitemid 46174816)
145. Vavricka SR, Van MJ, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002;36(1):164-172. (Pubitemid 34700774)
146. Ikemura K, Iwamoto T, Okuda M. Altered functions and expressions of drug transporters in liver, kidney and intestine in disorders of local and remote organs: possible role of oxidative stress in the pathogenesis. Expert Opin Drug Metab Toxicol. 2009; 5(8):907-920.
147. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12): 1147-1161.
148. Gupta NK, Lewis JH. Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther. 2008;28(9):1021-1041.
149. Lewis JH. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf. 2002;1(2):159-172.
150. Navarro VJ, Senior Jr. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731-739. (Pubitemid 43247143)
151. Amarapurkar DN. Prescribing medications in patients with decompensated liver cirrhosis. Int J Hepatol. 2011;2011:519526.
152. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-355.
153. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004;40(6):993-999. (Pubitemid 38670134)
154. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38(Suppl. 2):S80-S89. (Pubitemid 38328169)
155. Inductivo-Yu I, Bonacini M. Highly active antiretroviral therapyinduced liver injury. Curr Drug Saf. 2008;3(1):4-13. (Pubitemid 351227234)
156. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006;44(Suppl. 1):S132-S139. (Pubitemid 43053889)
157. Ogedegbe AO, Sulkowski MS. Antiretroviral-associated liver injury. Clin Liver Dis. 2003;7(2):475-499. (Pubitemid 36807742)
158. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186(1): 23-31. (Pubitemid 34666910)
159. Detkova Z, Lefebvre A, Bastide C, et al. Herbal medicines consumption for chronic liver disease and functional intestinal disorders: prospective study in 526 outpatients. Gastroenterology. 2001;120: (5) (Suppl. 1):A228.
160. Seeff LB, Curto TM, Szabo G, et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008;47(2): 605-612. (Pubitemid 351280729)
161. Navarro VJ. Herbal and dietary supplement hepatotoxicity. Semin Liver Dis. 2009;29(4):373-382.
162. Stedman C. Herbal hepatotoxicity. Semin Liver Dis. 2002;22(2): 195-206. (Pubitemid 34496472)
163. Donthamsetty S, Bhave VS, Mitra MS, Latendresse JR, Mehendale HM. Nonalcoholic fatty liver sensitizes rats to carbon tetrachloride hepatotoxicity. Hepatology. 2007;45(2):391-403. (Pubitemid 46374596)
164. Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res. 2007;37(6):410-415. (Pubitemid 46915785)
165. Rodriguez-Frias EA, Lee WM. Cancer chemotherapy I: hepatocellular injury. Clin Liver Dis. 2007;11(3):641-662, viii. (Pubitemid 47302346)
166. McDonald GB, Frieze D. A problem-oriented approach to liver disease in oncology patients. Gut. 2008;57(7):987-1003. (Pubitemid 351919535)
167. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci. 2002; 65(2):166-176. (Pubitemid 34121108)
168. Kim MJ, Skewes-Cox P, Fukushima H, et al. Functional characterization of liver enhancers that regulate drug-associated transporters. Clin Pharmacol Ther. 2011;89(4):571-578.